問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Psychiatry

更新時間:2023-09-19

鄭智銘
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

11Cases

2020-08-16 - 2024-12-31

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting5Sites

Terminated2Sites

2026-03-01 - 2029-12-31

Phase III

Active
A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease (ADAGIO-3)
  • Condition/Disease

    Alzheimer Disease, Agitation

  • Test Drug

    KarXT/KarX-EC

Participate Sites
5Sites

Recruiting5Sites

2026-07-01 - 2029-05-31

Phase III

Active
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
  • Condition/Disease

    Depressive Disorder, Treatment-Resistant

  • Test Drug

    鼻用噴液劑 鼻用噴液劑

Participate Sites
6Sites

Not yet recruiting4Sites

Recruiting2Sites

2025-09-01 - 2029-07-16

Phase III

Active
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
  • Condition/Disease

    Alzheimer Disease

  • Test Drug

    膠囊劑

Participate Sites
5Sites

Recruiting5Sites

2022-07-01 - 2024-09-20

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Not yet recruiting3Sites

Recruiting11Sites

Terminated2Sites

2022-08-01 - 2028-07-31

Others

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2023-04-01 - 2026-01-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-11-01 - 2028-07-31

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2023-01-01 - 2025-06-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-07-01 - 2030-05-31

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2